PubRank

Down Syndrome Memantine Follow-up Study

Clinical Trial ID NCT02304302

PubWeight™ 0.75‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02304302

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006. Birth Defects Res A Clin Mol Teratol 2010 7.00
2 Down's syndrome. Lancet 2003 5.10
3 Excitotoxic cell death. J Neurobiol 1992 4.76
4 The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999 3.98
5 Soluble oligomers of amyloid Beta protein facilitate hippocampal long-term depression by disrupting neuronal glutamate uptake. Neuron 2009 3.94
6 Deficits on subject-ordered tasks after frontal- and temporal-lobe lesions in man. Neuropsychologia 1982 3.56
7 Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system--too little activation is bad, too much is even worse. Neuropharmacology 2007 2.39
8 Clinical, social, and ethical implications of changing life expectancy in Down syndrome. Dev Med Child Neurol 2004 2.33
9 Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry 2000 2.26
10 Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 2005 2.25
11 Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia. Proc Natl Acad Sci U S A 1996 2.22
12 Regulation of NMDA channel function by endogenous Ca(2+)-dependent phosphatase. Nature 1994 2.07
13 The neuropsychology of Down syndrome: evidence for hippocampal dysfunction. Child Dev 2003 2.03
14 Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet 2012 1.88
15 Mismatch negativity: different water in the same river. Audiol Neurootol 2000 1.79
16 Alzheimer's disease in Down syndrome: neurobiology and risk. Ment Retard Dev Disabil Res Rev 2007 1.69
17 Early detection and differential diagnosis of Alzheimer's disease and depression with neuropsychological tasks. Dement Geriatr Cogn Disord 2001 1.66
18 The mismatch negativity: a powerful tool for cognitive neuroscience. Ear Hear 1995 1.64
19 Neuroinflammation and regulation of glial glutamate uptake in neurological disorders. J Neurosci Res 2007 1.59
20 Pharmacotherapy of Alzheimer disease. Can J Psychiatry 2007 1.43
21 Glutamate transporter alterations in Alzheimer disease are possibly associated with abnormal APP expression. J Neuropathol Exp Neurol 1997 1.42
22 Successful verbal encoding into episodic memory engages the posterior hippocampus: a parametrically analyzed functional magnetic resonance imaging study. J Neurosci 1998 1.41
23 Acute injections of the NMDA receptor antagonist memantine rescue performance deficits of the Ts65Dn mouse model of Down syndrome on a fear conditioning test. Neuropsychopharmacology 2007 1.35
24 Down syndrome and genetics - a case of linked histories. Nat Rev Genet 2005 1.31
25 Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability. J Child Neurol 2007 1.29
26 The role of memantine in the treatment of psychiatric disorders other than the dementias: a review of current preclinical and clinical evidence. CNS Drugs 2012 1.26
27 Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections. Br J Pharmacol 2012 1.26
28 Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol 1998 1.24
29 A retrospective study of memantine in children and adolescents with pervasive developmental disorders. Psychopharmacology (Berl) 2006 1.18
30 Activation of microglial N-methyl-D-aspartate receptors triggers inflammation and neuronal cell death in the developing and mature brain. Ann Neurol 2012 1.12
31 Effects of long-term memantine on memory and neuropathology in Ts65Dn mice, a model for Down syndrome. Behav Brain Res 2010 1.09
32 Six weeks to twenty-one years old: a longitudinal study of children with Down's syndrome and their families. Third Jack Tizard memorial lecture. J Child Psychol Psychiatry 1988 1.05
33 Open-label memantine in fragile X syndrome. J Autism Dev Disord 2009 1.04
34 Pharmacotherapies for Alzheimer's disease: beyond cholinesterase inhibitors. Pharmacol Ther 2011 1.03
35 Verbal short-term memory deficits in Down syndrome: a consequence of problems in rehearsal? J Child Psychol Psychiatry 2000 1.01
36 Glutamate receptors in preclinical research on Alzheimer's disease: update on recent advances. Pharmacol Biochem Behav 2011 0.98
37 Exaggerated NMDA mediated LTD in a mouse model of Down syndrome and pharmacological rescuing by memantine. Learn Mem 2011 0.98
38 Retracted Disturbed neurotransmitter transporter expression in Alzheimer's disease brain. J Alzheimers Dis 2011 0.98
39 Dose-related effects of memantine on a mismatch negativity-like response in anesthetized rats. Neuroscience 2010 0.97
40 Mismatch negativity (MMN) as an index of central auditory system plasticity. Int J Audiol 2008 0.92
41 The linguistic and cognitive profile of Down syndrome: evidence from a comparison with fragile X syndrome. Downs Syndr Res Pract 2001 0.91
42 A pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit/hyperactivity disorder combined type. J Child Adolesc Psychopharmacol 2007 0.91
43 Memantine pharmacotherapy: a naturalistic study using a population pharmacokinetic approach. Clin Pharmacokinet 2007 0.91
44 Effects of NMDA receptor antagonist memantine on mismatch negativity. Brain Res Bull 2007 0.90
45 Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome. J Alzheimers Dis 2010 0.90
46 Prospects for improving brain function in individuals with Down syndrome. CNS Drugs 2013 0.89
47 Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. Transl Psychiatry 2012 0.89
48 Stability and change in cognitive ability over the life span: a comparison of populations with and without Down's syndrome. J Intellect Disabil Res 2005 0.85
49 Serial order reconstruction in Down syndrome: evidence for a selective deficit in verbal short-term memory. J Child Psychol Psychiatry 2005 0.84
50 Memantine: a review of possible uses in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry 2013 0.84
51 The epidemiology of Alzheimer disease in intellectual disability: results and recommendations from an international conference. J Intellect Disabil Res 1997 0.84
52 Predictors of academic attainments of young people with Down's syndrome. J Intellect Disabil Res 2008 0.82
53 Verbal short-term memory in Down's syndrome: an articulatory loop deficit? J Intellect Disabil Res 2004 0.82
54 Language acquisition in special populations: a comparison between Down and Williams syndromes. Neuropsychologia 2002 0.82
55 Academic attainments of children with Down's syndrome: a longitudinal study. Br J Educ Psychol 2003 0.81
56 Alzheimer disease: Treatment of Alzheimer disease in Down syndrome. Nat Rev Neurol 2012 0.80
57 Digit span in individuals with Down syndrome and in typically developing children: temporal aspects. J Speech Lang Hear Res 2000 0.78
58 GABAergic deafferentation hypothesis of brain aging and Alzheimer's disease; pharmacologic profile of the benzodiazepine antagonist, flumazenil. Rev Neurosci 1996 0.76
59 Timing of therapies for Down syndrome: the sooner, the better. Front Behav Neurosci 2015 0.75
Next 100